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ABSTRACT
Objective: To determine if improvements in cognitive
outcome detected at 18 months’ corrected age (CA) in
infants born <33 weeks’ gestation receiving a high-
docosahexaenoic acid (DHA) compared with standard-
DHA diet were sustained in early childhood.
Design: Follow-up of a multicentre randomised
controlled trial. Randomisation was stratified for sex,
birth weight (<1250 vs ≥1250 g) and hospital.
Setting: Five Australian tertiary hospitals from 2008 to
2013.
Participants: 626 of the 657 participants randomised
between 2001 and 2005 were eligible to participate.
Interventions: High-DHA (≈1% total fatty acids)
enteral feeds compared with standard-DHA (≈0.3%
total fatty acids) from age 2–4 days until term CA.
Primary outcome: Full Scale IQ of the Wechsler
Abbreviated Scale of Intelligence (WASI) at 7 years CA.
Prespecified subgroup analyses based on the
randomisation strata (sex, birth weight) were conducted.
Results: 604 (92% of the 657 originally randomised)
consented to participate (291 high-DHA, 313 standard-
DHA). To address missing data in the 604 consenting
participants (22 for primary outcome), multiple
imputation was performed. The Full Scale IQ was not
significantly different between groups (high-DHA 98.3,
SD 14.0, standard-DHA 98.5, SD 14.9; mean difference
adjusted for sex, birthweight strata and hospital −0.3,
95% CI −2.9 to 2.2; p=0.79). There were no significant
differences in any secondary outcomes. In prespecified
subgroup analyses, there was a significant sex by
treatment interaction on measures of parent-reported
executive function and behaviour. Scores were within
the normal range but girls receiving the high-DHA diet
scored significantly higher (poorer outcome) compared
with girls receiving the standard-DHA diet.
Conclusions: Supplementing the diets of preterm
infants with a DHA dose of approximately 1% total fatty
acids from days 2–4 until term CA showed no evidence
of benefit at 7 years’ CA.
Trial registration number: Australian New Zealand
Clinical Trials Registry: ACTRN12606000327583.
INTRODUCTION
With advances in clinical care, increasing
numbers of very preterm infants are surviv-
ing into childhood. However, neurobeha-
vioural impairments have not decreased,
imposing an increasing burden on health
and education systems. There remains an
inverse relationship between cognitive func-
tioning and gestational age, with the most
preterm survivors being most affected by
poor cognitive functioning.1
The long chain polyunsaturated fatty acid
docosahexaenoic acid (DHA; 22:6 n-3) is a
Strengths and limitations of this study
▪ First study to evaluate the effect a diet that pro-
vides the estimated in utero accretion rate of
docosahexaenoic acid in infancy has on neurode-
velopmental outcomes in early childhood.
▪ Sample size large enough to detect a four-point
difference in Full Scale IQ if it existed.
▪ Low risk of bias achieved through minimal attri-
tion rate (92% of children originally randomised
consented to participate) and blinding of
research personnel, outcome assessors and all
but 12 families.
▪ Robust objective assessments of neurodevelop-
mental outcomes undertaken by psychologists
after extensive training and ongoing auditing.
▪ A limitation of the study was not including a
teacher assessment of the child’s behaviour.
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major lipid in the brain and is known to be involved in
neurogenesis and neurite growth.2 Infants born very
preterm are deprived of the placental supply of DHA that
occurs in the last trimester of pregnancy and have lower
brain concentrations of DHA than term-born infants,3
possibly contributing to their high risk of developmental
delay. The only trials where the dose of DHA has
matched the estimated in utero accretion rate of DHA
(≈45 mg/kg/day)4 and was inclusive of breast milk
feeding have shown some short-term beneﬁt of DHA sup-
plementation.5–7 The DHA for the Improvement of
Neurodevelopmental Outcome in preterm infants
(DINO) trial is the largest published trial of DHA supple-
mentation in very preterm infants.6 The DINO trial
showed that although mean cognitive development at
18 months’ corrected age (CA) was not altered overall,
the proportion of infants with severe developmental
delay was signiﬁcantly reduced. In prespeciﬁed subgroup
analyses, the greatest effect was seen in girls and there
was a strong suggestion of beneﬁt in the smallest infants.6
Assessing neurodevelopment within the ﬁrst 2 years of
life remains a cornerstone of preterm infant follow-up
ensuring early detection of problems and initiation of
appropriate support services. However, developmental
outcomes measured in the ﬁrst 2 years may not accur-
ately predict a longer term developmental outcome.8 9
Related to this, some cognitive domains that are
hypothesised to be inﬂuenced by DHA, such as execu-
tive function and memory, are difﬁcult to reliably assess
in early childhood. We therefore aimed to determine
the effect of DHA given up to term equivalent to infants
born less than 33 weeks’ gestation, on neurodevelop-
ment at 7 years’ CA.
METHODS
This is a follow-up at 7-years’ CA of infants who partici-
pated in the DINO randomised controlled trial.
Initial study—the DINO trial
The DINO trial methods have been previously pub-
lished.6 Between 2001 and 2005, 657 infants born
<33 weeks’ gestation from ﬁve Australian tertiary hospitals
were randomised, from within 5 days of their ﬁrst enteral
feed, to receive a high-DHA or standard-DHA diet until
40 weeks’ CA. Infants were excluded if they had a major
congenital or chromosomal abnormality, were from a
multiple birth in which not all live-born infants were eli-
gible, were in other trials of fatty acid supplementation,
or if ﬁsh oil was contraindicated in the lactating mother.
Mother–infant pairs were randomly assigned a unique
study number using a computer-driven telephone ran-
domisation service according to an independently gener-
ated randomisation schedule. Stratiﬁcation was by centre,
birth weight (<1250 and ≥1250 g) and infant sex.
Multiple births were considered a single randomisation
unit. Participants were enrolled and assigned to their
study group by research nurses at each centre.
Dietary treatments
Lactating women with infants randomised to the
high-DHA group took DHA-rich tuna oil capsules daily to
achieve a breast milk DHA concentration ≈1% of total
fatty acids without altering the naturally occurring con-
centration of arachidonic acid. Infants requiring formula
received a high-DHA preterm formula (≈1.0% DHA and
≈0.6% AA). The high-DHA diet provided ≈50 mg/kg/
day of DHA. Lactating women with infants randomised to
standard-DHA took placebo soy oil capsules. Infants
requiring formula received standard preterm infant
formula (≈0.35% DHA). The standard-DHA diet pro-
vided ≈20 mg/kg/day of DHA. Postdischarge, women
who were breast feeding were encouraged to continue,
and those using formula were encouraged to use a com-
mercially available term formula supplemented with
DHA. Parents, clinicians and all research personnel were
blinded to the participant study group.
Present study—follow-up at 7 years’ CA
The parent or guardian of each participant provided
written informed consent. A letter of invitation was sent
to caregivers of eligible children followed by a telephone
call. Of the 657 infants randomised to the DINO trial,
626 children were eligible to participate in the 7-year CA
follow-up (ie, had not withdrawn from the study or
died). Clinicians and researchers remained unaware of
group allocations; the statistician was unblinded during
the 18-month CA analysis of the DINO results. Twelve
families (6 children in each group) requested to be
unblinded after publication of the 18-month CA results.
Assessments were administered by trained psychologists
blinded to group allocation and the 18-month CA assess-
ment results. Assessments were conducted at the partici-
pating perinatal centre; if this was unsuitable for the
family, assessments were conducted elsewhere. The
assessment, including short breaks, took 3 h and was
conducted within ±3 months of the 7-year CA date. In
difﬁcult to locate families, efforts to conduct an assess-
ment continued beyond this age. The child’s CA
(chronological age reduced by the number of weeks
born before 40 weeks of gestation) was used to calculate
age-standardised test scores, thus avoiding a known bias
in cognitive scores which we have reported to be clinic-
ally important at all ages through childhood.10
Primary outcome
The primary outcome was general intellectual ability as
assessed by the Full Scale IQ of the Wechsler
Abbreviated Scale of Intelligence (WASI). The WASI
consists of four subtests (Vocabulary, Similarities, Block
Design and Matrix Reasoning) and provides a brief and
reliable estimate of the child’s intellectual functioning.
These four subtests yield the Full Scale IQ which is age
standardised with a mean of 100 (SD 15). In the event
that children had a recent Full Scale IQ assessment
using a different psychological test, the results from that
test were used.
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Secondary outcomes
Secondary outcomes included cognitive domains that have
been previously demonstrated to be areas of concern for
preterm children, as well as those domains thought to be
sensitive to DHA depletion and included intellectual
impairment, Verbal and Performance IQ, attention,
memory and learning, executive functioning, behaviour,
visual-spatial perceptual skills, educational progress and
quality of life. Intellectual impairment, assessed using the
WASI Full Scale IQ, was deﬁned as mild (IQ <85) and
major (IQ <70). Verbal and performance IQ scores were
acquired from the WASI. Subtests of the Test of Everyday
Attention for Children measured selective attention (Sky
Search), sustained attention (Score!), shifting attention/
attentional control (Creature Counting) and divided
attention (Sky Search Dual Task).11 The score for Divided
Attention was calculated by multiplying the proportion of
visual stimuli found by the proportion of auditory stimuli
counted, multiplied by 10 (with 10 signifying a perfect
score).12 Aspects of executive functioning were assessed
with the Rey Complex Figure, the Fruit Stroop Test and
the parent-completed Behaviour Rating Inventory of
Executive Functioning (BRIEF).
Short-term verbal memory and learning were assessed
with the Rey Auditory Verbal Learning Test. Visual
Perception was assessed with the Visual-Spatial Relations,
Visual Figure-Ground and Visual Closure subtests of the
Test of Visual Perceptual Skills, third edition.
Educational progress was assessed with the Word
Reading, Spelling, and Math Computation subtests of
the Wide Range Achievement Test fourth edition.
Parents were also questioned on whether their child had
repeated a year at school.
Child behaviour was assessed with two parent-completed
questionnaires; the Conners 3rd Edition ADHD Index
(Conners 3 AI-parent) which screens for Attention Deﬁcit
Hyperactivity Disorder (ADHD), and the Strengths and
Difﬁculties Questionnaire which screens for emotional
and behaviour problems. General health status and
health-related quality of life were measured using parent-
completed questionnaires: the Multi-attributed Health
Status Classiﬁcation System—Health Utilities Index Mark
3 and the Pediatric Quality of Life Inventory.
Information on family functioning (Family Assessment
Device), and recent family events (Recent Life Events
Questionnaire) were collected through parent-completed
questionnaires. General child health, home environment,
DHA containing diet and supplement use were collected.
If the child was unable to complete an assessment due
to severe developmental delay, they were assigned the
lowest possible score. Outcome scores were recorded as
missing if the child was uncooperative or they were
untestable due to a motor or sensory impairment.
SAMPLE SIZE AND STATISTICAL ANALYSIS
This follow-up study was designed in 2007 before the
18-month CA assessments had been completed. We
anticipated a follow-up rate of at least 90% at 7 years, that
is, >590 children (295 per group). Using blinded
18-month Mental Development Index results available at
the time, we estimated that the design effect due to the
non-independence of multiple births was 1.14 (intraclass
correlation coefﬁcient (ICC)=0.70, average of 1.20 infants
per mother), giving an effective sample size of 259 chil-
dren per group at 7 years. With these assumptions, we had
85% power (α=0.05) to detect a four-point minimum dif-
ference in the Full Scale IQ scores (SD 15) between
groups. In prespeciﬁed subgroup analyses by randomisa-
tion strata (sex and birth weight <1250 g), we had 85%
power (α=0.05) to detect a six-point difference (SD 15).
Data management and analysis
All participants who consented to participate in the
7-year CA follow-up (whether they completed the assess-
ments or not) were analysed according to the group to
which they were allocated. To address missing outcome
data, multiple imputation was performed separately by
treatment group using chained equations13 to create 100
complete data sets, under the assumption that data were
missing at random. Imputation models included covari-
ates prespeciﬁed for adjustment and auxiliary variables
that helped to satisfy the missing at random assumption
or that were predictive of outcomes. Following analysis,
the effect estimates from the imputed data sets were
combined using Rubin’s rules.14 The primary analysis
was based on imputed data and included all participants
who consented to the follow-up study. Sensitivity analyses
were performed on the available data and on imputed
data for the 657 children in the original sample, exclud-
ing deaths. All analyses produced similar results and
only the results of the primary analysis are presented.
Outcomes were analysed using generalised estimating
equations (GEE) to account for clustering due to mul-
tiple births. Normally distributed outcomes were ana-
lysed using a linear GEE, with the effect of treatment
expressed as a mean difference with 95% CI. Binary out-
comes were analysed using log-binomial GEE, with the
effect of treatment expressed as a relative risk (RR) with
95% CI. Unadjusted and adjusted analyses were per-
formed, with adjustment for the stratiﬁcation variables
(centre, birth weight, sex). Statistical signiﬁcance was
assessed at the two-sided p<0.05 level. All analyses fol-
lowed a prespeciﬁed statistical analysis plan and were
performed using SAS V.9.3 (Cary, North Carolina, USA)
and Stata Release V.12 (Statacorp LP, College Station,
Texas, USA).
RESULTS
Study participants
The participant ﬂow for infants randomly assigned to
receive the high-DHA or standard-DHA diet and assessed
at 7 years’ CA is shown in the ﬁgure 1. Follow-up assess-
ments began in June 2008 and ended on 10 July 2013. In
total, 604 families consented to participate in the 7-year
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follow-up (92% of the 657 originally randomised).
Adequate data for analysis of the primary outcome (Full
Scale IQ) were available for 582 (89%) of the 657 rando-
mised children and 93% of the 626 children eligible for
the 7-year follow-up (high-DHA n=286, standard-DHA
n=296; ﬁgure 1). Twenty children (high-DHA n=8,
standard-DHA n=12) were assessed using a different IQ
measure (Wechsler Preschool and Primary Scale of
Intelligence n=17; Wechsler Intelligence Scale for
Children n=2; or Differential Ability Scales n=1) because
of their involvement in other studies.
The characteristics of the 604 children consenting to
follow-up were similar at randomisation (table 1). Two
children (both in the standard-DHA group) died
between 18 months’ and 7 years’ CA (table 2); their
deaths were reviewed by an independent Mortality
Review Committee blinded to treatment group and
deemed to be unrelated to the study product or proto-
col. Children were assessed at a mean of 7.2 years’ CA
(table 2). Family functioning and life events affecting
the children were similar between groups based on
scores from the Family Assessment Device and Recent
Life Events (table 2). English was the primary language
spoken at home for the majority of children and the
consumption of DHA containing foods or supplements
was similar between groups (table 2).
Primary outcome at 7 years’ CA
The Full Scale IQ was not signiﬁcantly different between
the two groups (high-DHA 98.3, SD 14.0, standard-DHA
98.5, SD 14.9; mean difference adjusted for sex, birth
weight (<1250 or ≥1250 g) and the recruiting centre
−0.3, 95% CI −2.9 to 2.2; p=0.79) (table 3).
Secondary outcomes at 7 years’ CA
Intellectual impairment, that is, a Full Scale IQ <85 or <70
did not differ signiﬁcantly between the groups (table 3),
Figure 1 DINO trial participant flow in the 7-year follow-up.
CA, corrected age; DHA, docosahexaenoic acid; DINO,
Docosahexaenoic acid for the Improvement of
Neurodevelopmental Outcome in preterm infants; EDD,
expected date of delivery.
Table 1 Baseline (at randomisation) clinical and demographic characteristics
High-DHA
diet (n=291)
Standard-DHA
diet (n=313)
Median (IQR) gestational age (weeks) 30.0 (28.0–31.0) 30.0 (28.0–31.0)
Mean (SD) birth weight (g) 1307 (420) 1320 (410)
Male sex 152 (52.2) 172 (55.0)
Singleton birth 208 (71.5) 195 (62.3)
Birth weight <1250 g 132 (45.4) 139 (44.4)
Birth weight <10th centile* 54 (18.6) 57 (18.2)
Mean (SD) birth length (cm) (n=222/238)† 38.2 (3.9) 38.2 (4.1)
Mean (SD) birth head circumference (cm) (n=248/261)† 27.2 (2.8) 27.4 (2.7)
Mean (SD) maternal age (years) 29.9 (5.7) 30.5 (5.2)
Mother smoked during pregnancy 77 (26.5) 76 (24.3)
Infant received breast milk at trial entry 271 (93.1) 291 (93.0)
Mother completed secondary education (n=280/293)† 175 (62.5) 172 (58.7)
Father completed secondary education (n=270/280)† 146 (54.1) 155 (55.4)
Values are numbers (percentage) of infants unless stated otherwise.
*The 10th centile for gestational age in a normal population as reported by Cole et al.31
†Numerical data available for high-DHA and standard-DHA, respectively.
DHA, docosahexaenoic acid.
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and nor did the Verbal and Performance IQ scores
(table 3). There was no effect of the high-DHA diet on
selective, sustained, shifting or divided attention, short-
term verbal memory or learning ability, executive function-
ing, visual perception or academic achievement (table 4).
According to parental reports, there were no differ-
ences between the high-DHA and standard-DHA groups
in executive functioning, ADHD symptoms, emotional
and behaviour problems, general health status,
health-related quality of life or in the percentage of
children repeating a school year (table 5). The
parent-reported health-related quality of life neared
‘perfect health’ (score of 1) for both groups.
Furthermore, parental reports of a diagnosis of ADHD
(high-DHA 9/285, 3.2%; standard-DHA 7/298, 2.3%;
RR=1.34, 95% CI 0.51 to 3.56; p=0.55), ADHD and using
medication (high-DHA 6/285, 2.1%; standard-DHA 4/
298, 1.3%; RR=1.57, 95% CI 0.45 to 5.50; p=0.48) autism
spectrum disorder (high-DHA 10/285, 3.5%;
standard-DHA 9/298, 3.0%; RR=1.16, 95% CI 0.48 to
2.82; p=0.74) or cerebral palsy (high-DHA 14/285, 4.9%;
standard-DHA 9/298, 3.0%; RR=1.63, 95% CI 0.72 to
3.70; p=0.25) did not differ signiﬁcantly between groups.
Subgroup analysis by randomisation strata—sex
There was no interaction effect between dietary treat-
ment and sex for the primary outcome Full Scale IQ
(see web appendix A).
Table 2 Postrandomisation treatment group comparison of demographic, social and clinical characteristics
High-DHA
diet (n=291)
Standard-DHA
diet (n=313) p Value
Social variables
Mean, SD corrected age at primary outcome assessment, years (n=284/293) 7.2 (0.4) 7.2 (0.3) 0.69
Death between 18 months and 7 years’ corrected age (n=313/326*) 0 (0.0) 2 (0.6) 0.50†
Family unblinded before the 7-year corrected age assessment 6 (2.1) 6 (1.9) >0.99
English primary language spoken at home (n=285/298) 278 (97.5) 296 (99.3) 0.10
Living in two parent family‡ (n=285/298) 214 (75.1) 237 (79.5) 0.23†
Mean (SD) Recent Life Events, total events (n=278/290) 2.5 (2.5) 2.2 (2.4) 0.20
Mean (SD) Recent Life Events, total events still impacting (n=278/290) 0.5 (1.2) 0.4 (1.0) 0.47
Mean (SD) Family Assessment Device general functioning score (n=278/289) 1.6 (0.4) 1.5 (0.4) 0.24
Dietary variables
Had fish in the last month (n=285/298) 248 (87.0) 267 (89.6) 0.39
Mean (SD) number of fish meals in the last month (n=246/266) 5.0 (3.8) 5.1 (3.6) 0.96
Had DHA-enriched foods in the last month (n=285/298) 172 (60.4) 181 (60.7) 0.93
Mean (SD) number of DHA-enriched foods in the last month (n=164/173) 21.2 (26.4) 16.8 (18.2) 0.16
Had a supplement containing DHA in the last month (n=283/293) 73 (25.8) 57 (19.5) 0.10
Values are numbers (percentage) of infants unless stated otherwise.
*Denominator based on randomised infants still alive at the completion of DINO.
†Fisher exact p Value.
‡Families with biological parents living together and new marriage/de facto relationship.
DHA, docosahexaenoic acid; DINO, DHA for the Improvement of Neurodevelopmental Outcome in preterm infants trial.
Table 3 Primary and secondary outcomes from the Wechsler Abbreviated Scale of Intelligence* at 7 years’ corrected age
Outcome
High-DHA
diet mean
(SD) N=291
Standard-DHA
diet mean (SD)
N=313
Unadjusted
treatment effect
(95% CI)
Unadjusted
p Value
Adjusted
treatment effect
(95% CI)†
Adjusted
p Value†
Primary
Full Scale IQ 98.3 (14.0) 98.5 (14.9) −0.3 (−2.9 to 2.4) 0.85 −0.3 (−2.9 to 2.2) 0.79
Secondary
Verbal IQ 98.0 (14.2) 98.8 (15.8) −0.7 (−3.5 to 2.0) 0.59 −0.9 (−3.5 to 1.8) 0.52
Performance IQ 98.5 (14.5) 98.5 (13.6) 0.0 (−2.5 to 2.6) 0.98 −0.0 (−2.5 to 2.5) 0.99
Number (%) Full Scale
IQ <85‡
40 (13.6) 44 (14.1) 1.0 (0.6 to 1.5) 0.87 1.0 (0.6 to 1.5) 0.84
Number (%) Full Scale
IQ <70§ (n=286/296)
3 (1.0) 5 (1.7) 0.73
Values are mean (SD) and treatment effects are mean difference based on imputed data unless otherwise indicated.
*Wechsler Abbreviated Scale of Intelligence IQ, the mean (SD) score is 100 (15), range 50–160.
†Adjusted for sex, birth weight (<1250 or ≥1250 g) and recruiting centre.
‡Treatment effect is relative risk.
§Raw data used due to the small number of cases; compared using the Fisher exact test.
DHA, docosahexaenoic acid.
Collins CT, et al. BMJ Open 2015;5:e007314. doi:10.1136/bmjopen-2014-007314 5
Open Access
group.bmj.com on February 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Ta
b
le
4
S
ec
on
da
ry
de
ve
lo
pm
en
ta
lo
ut
co
m
es
O
u
tc
o
m
e
H
ig
h
-D
H
A
d
ie
t
m
ea
n
(S
D
)
N
=2
91
S
ta
n
d
ar
d
-D
H
A
d
ie
t
m
ea
n
(S
D
)
N
=3
13
U
n
ad
ju
st
ed
m
ea
n
d
iff
er
en
ce
(9
5%
C
I)
U
n
ad
ju
st
ed
p
V
al
u
e
A
d
ju
st
ed
m
ea
n
d
iff
er
en
ce
(9
5%
C
I)*
A
d
ju
st
ed
p
V
al
u
e*
T
es
t
of
E
ve
ry
da
y
A
tte
nt
io
n
fo
r
C
hi
ld
re
n†
S
ky
se
ar
ch
nu
m
be
r
co
rr
ec
t
sc
al
e
sc
or
e‡
8.
9
(3
.7
)
8.
9
(3
.8
)
0.
0
(−
0.
6
to
0.
7)
0.
96
0.
0
(−
0.
6
to
0.
7)
0.
89
S
co
re
!
nu
m
be
r
co
rr
ec
t
sc
al
e
sc
or
e§
8.
1
(3
.8
)
8.
0
(3
.6
)
0.
1
(−
0.
6
to
0.
7)
0.
79
0.
1
(−
0.
6
to
0.
7)
0.
79
C
re
at
ur
e
co
un
tin
g
nu
m
be
r
co
rr
ec
ts
ca
le
sc
or
e¶
7.
7
(3
.6
)
8.
0
(3
.4
)
−
0.
3
(−
0.
9
to
0.
3)
0.
36
−
0.
3
(−
0.
9
to
0.
3)
0.
36
S
ky
se
ar
ch
du
al
ta
sk
co
m
po
si
te
sc
or
e*
*
4.
2
(2
.8
)
4.
4
(2
.9
)
−
0.
1
(−
0.
6
to
0.
4)
0.
67
−
0.
1
(−
0.
6
to
0.
4)
0.
66
R
ey
A
ud
ito
ry
V
er
ba
lL
ea
rn
in
g
T
es
t†
†
T
ria
l1
co
rr
ec
t
w
or
ds
4.
4
(2
.0
)
4.
3
(2
.0
)
0.
1
(−
0.
3
to
0.
4)
0.
71
0.
1
(−
0.
3
to
0.
4)
0.
68
T
ot
al
(t
ria
ls
1–
5)
co
rr
ec
t
w
or
ds
34
.4
(1
2.
1)
34
.8
(1
0.
8)
−
0.
4
(−
2.
3
to
1.
6)
0.
71
−
0.
3
(−
2.
2
to
1.
5)
0.
72
T
ot
al
in
tr
us
io
ns
2.
1
(3
.5
)
2.
5
(4
.0
)
−
0.
4
(−
1.
0
to
0.
3)
0.
25
−
0.
4
(−
1.
0
to
0.
3)
0.
25
T
ot
al
re
pe
tit
io
ns
4.
0
(4
.5
)
3.
7
(4
.1
)
0.
3
(−
0.
4
to
1.
0)
0.
45
0.
3
(−
0.
4
to
1.
0)
0.
44
D
el
ay
ed
re
ca
ll
co
rr
ec
t
w
or
ds
7.
3
(3
.5
)
7.
2
(3
.0
)
0.
2
(−
0.
4
to
0.
7)
0.
58
0.
1
(−
0.
4
to
0.
7)
0.
57
D
el
ay
ed
re
co
gn
iti
on
co
rr
ec
t
w
or
ds
13
.3
(2
.6
)
13
.1
(3
.0
)
0.
2
(−
0.
3
to
0.
6)
0.
50
0.
2
(−
0.
3
to
0.
6)
0.
50
R
ey
C
om
pl
ex
F
ig
ur
e‡
‡
C
op
y
ra
w
sc
or
e
16
.6
(7
.4
)
16
.3
(7
.8
)
0.
3
(−
1.
0
to
1.
6)
0.
66
0.
3
(−
0.
9
to
1.
6)
0.
61
D
el
ay
ed
re
ca
ll
ra
w
sc
or
e
7.
6
(4
.9
)
7.
0
(5
.0
)
0.
6
(−
0.
3
to
1.
4)
0.
18
0.
6
(−
0.
2
to
1.
4)
0.
17
O
rg
an
is
at
io
na
lr
aw
sc
or
e
3.
4
(1
.2
)
3.
3
(1
.2
)
0.
1
(−
0.
1
to
0.
3)
0.
57
0.
1
(−
0.
1
to
0.
3)
0.
52
F
ru
it
S
tr
oo
p
T
es
t§
§
In
te
rf
er
en
ce
sc
or
e
1.
0
(5
.8
)
1.
1
(5
.4
)
−
0.
2
(−
1.
1
to
0.
8)
0.
75
−
0.
2
(−
1.
1
to
0.
8)
0.
75
T
es
t
of
V
is
ua
lP
er
ce
pt
io
n
S
ki
lls
th
ird
ed
iti
on
¶¶
V
is
ua
ld
is
cr
im
in
at
io
n
st
an
da
rd
sc
or
e
8.
1
(3
.1
)
8.
1
(3
.6
)
−
0.
0
(−
0.
6
to
0.
5)
0.
95
−
0.
0
(−
0.
6
to
0.
5)
0.
96
F
ig
ur
e
gr
ou
nd
st
an
da
rd
sc
or
e
9.
4
(3
.8
)
9.
6
(4
.3
)
−
0.
2
(−
0.
9
to
0.
5)
0.
62
−
0.
2
(−
0.
9
to
0.
5)
0.
55
V
is
ua
lc
lo
su
re
st
an
da
rd
sc
or
e
7.
6
(3
.6
)
8.
0
(3
.7
)
−
0.
4
(−
1.
1
to
0.
2)
0.
15
−
0.
4
(−
1.
1
to
0.
2)
0.
16
W
id
e
R
an
ge
A
ch
ie
ve
m
en
tT
es
tf
ou
rt
h
ed
iti
on
**
*
W
or
d
re
ad
in
g
st
an
da
rd
sc
or
e
10
2.
2
(1
6.
0)
10
1.
5
(1
8.
4)
0.
8
(−
2.
2
to
3.
8)
0.
62
0.
6
(−
2.
4
to
3.
6)
0.
68
S
pe
lli
ng
st
an
da
rd
sc
or
e
97
.5
(1
6.
4)
98
.0
(1
7.
1)
−
0.
5
(−
3.
4
to
2.
4)
0.
74
−
0.
7
(−
3.
5
to
2.
2)
0.
65
M
at
h
co
m
pu
ta
tio
n
st
an
da
rd
sc
or
e
90
.8
(1
5.
0)
90
.6
(1
5.
0)
0.
2
(−
2.
5
to
2.
9)
0.
88
0.
2
(−
2.
4
to
2.
8)
0.
87
V
al
ue
s
ar
e
m
ea
n
(S
D
)
an
d
tre
at
m
en
t
ef
fe
ct
s
ar
e
m
ea
n
di
ffe
re
nc
e
ba
se
d
on
im
pu
te
d
da
ta
un
le
ss
ot
he
rw
is
e
in
di
ca
te
d.
*A
dj
us
te
d
fo
r
se
x,
bi
rt
h
w
ei
gh
t
(<
12
50
or
≥
12
50
g)
an
d
re
cr
ui
tin
g
ce
nt
re
.
†
M
ea
su
re
s
at
te
nt
io
n;
th
e
m
ea
n
sc
al
e
sc
or
e
is
10
,
ra
ng
e
8–
12
;
an
at
te
nt
io
n
sc
al
e
sc
or
e
of
le
ss
th
an
8
is
in
di
ca
tiv
e
of
po
or
at
te
nt
io
n;
th
e
co
m
po
si
te
sc
or
e
is
no
ts
ta
nd
ar
di
se
d.
‡
S
el
ec
tiv
e
at
te
nt
io
n
m
ea
su
re
.
§S
us
ta
in
ed
at
te
nt
io
n
m
ea
su
re
.
¶A
tte
nt
io
na
lc
on
tro
lm
ea
su
re
.
**
D
iv
id
ed
at
te
nt
io
n
m
ea
su
re
.
†
†
M
ea
su
re
s
ex
ec
ut
iv
e
fu
nc
tio
n
(v
er
ba
ll
ea
rn
in
g
m
em
or
y)
.
‡
‡
M
ea
su
re
s
ex
ec
ut
iv
e
fu
nc
tio
n
(v
is
uo
sp
at
ia
la
bi
lit
ie
s
an
d
vi
su
os
pa
tia
lm
em
or
y)
.
§§
M
ea
su
re
s
ex
ec
ut
iv
e
fu
nc
tio
n
(in
hi
bi
to
ry
co
nt
ro
l)
.
¶¶
M
ea
su
re
s
vi
su
al
pe
rc
ep
tu
al
sk
ill
s;
th
e
m
ea
n
(S
D
)
sc
or
e
is
10
(3
),
ra
ng
e
8–
12
;
a
sc
or
e
of
le
ss
th
an
8
in
di
ca
te
s
po
or
vi
su
al
pe
rc
ep
tu
al
sk
ill
s.
**
*M
ea
su
re
s
ed
uc
at
io
na
lp
ro
gr
es
s;
th
e
m
ea
n
(S
D
)
sc
or
e
is
10
0
(1
5)
.
D
H
A
,d
oc
os
ah
ex
ae
no
ic
ac
id
.
6 Collins CT, et al. BMJ Open 2015;5:e007314. doi:10.1136/bmjopen-2014-007314
Open Access
group.bmj.com on February 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Ta
b
le
5
P
ar
en
t-
re
po
rt
ed
he
al
th
,w
el
l-b
ei
ng
an
d
ed
uc
at
io
n
ou
tc
om
es
.
O
u
tc
o
m
e
H
ig
h
-D
H
A
d
ie
t
m
ea
n
(S
D
)
N
=2
91
S
ta
n
d
ar
d
-D
H
A
d
ie
t
m
ea
n
(S
D
)
N
=3
13
U
n
ad
ju
st
ed
m
ea
n
d
iff
er
en
ce
(9
5%
C
I)
U
n
ad
ju
st
ed
p
V
al
u
e
A
d
ju
st
ed
m
ea
n
d
iff
er
en
ce
(9
5%
C
I)*
A
d
ju
st
ed
p
V
al
u
e*
B
R
IE
F
†
B
eh
av
io
ur
al
re
gu
la
tio
n
in
de
x
53
.7
(1
2.
4)
51
.8
(1
2.
5)
1.
9
(−
0.
3
to
4.
1)
0.
09
1.
9
(−
0.
3
to
4.
0)
0.
09
In
hi
bi
t
sc
al
e
53
.3
(1
1.
4)
51
.6
(1
1.
5)
1.
8
(−
0.
2
to
3.
8)
0.
08
1.
7
(−
0.
2
to
3.
7)
0.
09
S
hi
ft
sc
al
e
53
.6
(1
3.
0)
51
.7
(1
2.
6)
1.
9
(−
0.
3
to
4.
1)
0.
10
1.
8
(−
0.
4
to
4.
0)
0.
10
E
m
ot
io
na
lc
on
tr
ol
sc
al
e
53
.2
(1
2.
3)
51
.8
(1
2.
7)
1.
4
(−
0.
8
to
3.
5)
0.
23
1.
3
(−
0.
8
to
3.
5)
0.
23
M
et
ac
og
ni
tio
n
in
de
x
54
.9
(1
2.
6)
53
.9
(1
2.
8)
0.
9
(−
1.
3
to
3.
1)
0.
43
0.
8
(−
1.
4
to
3.
0)
0.
48
In
iti
at
e
sc
al
e
53
.1
(1
1.
6)
52
.4
(1
1.
6)
0.
7
(−
1.
3
to
2.
8)
0.
49
0.
6
(−
1.
4
to
2.
7)
0.
54
W
or
ki
ng
m
em
or
y
sc
al
e
55
.5
(1
3.
4)
55
.1
(1
3.
7)
0.
4
(−
1.
9
to
2.
7)
0.
75
0.
3
(−
2.
0
to
2.
5)
0.
81
P
la
n/
or
ga
ni
se
sc
al
e
56
.0
(1
3.
4)
55
.4
(1
3.
3)
0.
6
(−
1.
7
to
3.
0)
0.
61
0.
5
(−
1.
8
to
2.
8)
0.
67
O
rg
an
is
at
io
n
of
m
at
er
ia
ls
sc
al
e
53
.1
(1
0.
7)
52
.1
(1
0.
9)
1.
1
(−
0.
8
to
3.
0)
0.
27
1.
0
(−
0.
9
to
2.
9)
0.
28
M
on
ito
r
sc
al
e
53
.0
(1
2.
8)
52
.4
(1
3.
1)
0.
6
(−
1.
6
to
2.
9)
0.
58
0.
5
(−
1.
7
to
2.
7)
0.
64
G
lo
ba
le
xe
cu
tiv
e
co
m
po
si
te
(t
ot
al
sc
or
e)
55
.0
(1
2.
5)
53
.6
(1
2.
9)
1.
4
(−
0.
9
to
3.
6)
0.
24
1.
3
(−
1.
0
to
3.
5)
0.
26
A
D
H
D
(C
on
ne
rs
3
A
I-
pa
re
nt
)‡
A
D
H
D
ts
co
re
(t
ot
al
sc
or
e)
65
.6
(1
8.
5)
64
.4
(1
8.
7)
1.
3
(−
1.
9
to
4.
4)
0.
43
1.
1
(−
2.
0
to
4.
2)
0.
47
S
tr
en
gt
hs
an
d
D
iff
ic
ul
tie
s
Q
ue
st
io
nn
ai
re
§
E
m
ot
io
na
ls
ym
pt
om
s
sc
or
e
2.
4
(2
.2
)
2.
3
(2
.1
)
0.
2
(−
0.
2
to
0.
6)
0.
33
0.
2
(−
0.
2
to
0.
5)
0.
35
C
on
du
ct
pr
ob
le
m
s
sc
or
e
2.
1
(1
.9
)
1.
9
(1
.8
)
0.
2
(−
0.
1
to
0.
5)
0.
20
0.
2
(−
0.
1
to
0.
5)
0.
18
H
yp
er
ac
tiv
ity
sc
or
e
4.
4
(2
.8
)
4.
3
(2
.8
)
0.
1
(−
0.
4
to
0.
6)
0.
72
0.
1
(−
0.
3
to
0.
6)
0.
66
P
ee
r
pr
ob
le
m
s
sc
or
e
1.
8
(1
.9
)
1.
6
(1
.7
)
0.
2
(−
0.
1
to
0.
5)
0.
16
0.
2
(−
0.
1
to
0.
5)
0.
16
P
ro
so
ci
al
B
eh
av
io
ur
sc
or
e
8.
2
(1
.9
)
8.
1
(2
.0
)
0.
1
(−
0.
2
to
0.
4)
0.
52
0.
1
(−
0.
2
to
0.
4)
0.
52
Im
pa
ct
sc
or
e
0.
9
(1
.9
)
0.
9
(1
.7
)
0.
0
(−
0.
3
to
0.
3)
0.
86
0.
0
(−
0.
3
to
0.
3)
0.
82
T
ot
al
D
iff
ic
ul
tie
s
sc
or
e
10
.8
(6
.7
)
10
.1
(6
.2
)
0.
7
(−
0.
4
to
1.
8)
0.
22
0.
7
(−
0.
4
to
1.
8)
0.
21
H
ea
lth
U
til
iti
es
In
de
x
M
ar
k
3¶
V
is
io
n
sc
or
e
0.
98
(0
.0
6)
0.
98
(0
.0
8)
0.
00
(−
0.
01
to
0.
01
)
0.
84
0.
00
(−
0.
01
to
0.
01
)
0.
89
H
ea
rin
g
sc
or
e
1.
00
(0
.0
3)
1.
00
(0
.0
4)
−
0.
00
(−
0.
01
to
0.
00
)
0.
71
−
0.
00
(−
0.
01
to
0.
00
)
0.
75
S
pe
ec
h
sc
or
e
0.
96
(0
.1
2)
0.
94
(0
.1
4)
0.
02
(−
0.
00
to
0.
04
)
0.
12
0.
02
(−
0.
00
to
0.
04
)
0.
12
A
m
bu
la
tio
n
sc
or
e
0.
98
(0
.1
1)
0.
99
(0
.0
9)
−
0.
01
(−
0.
02
to
0.
01
)
0.
39
−
0.
01
(−
0.
02
to
0.
01
)
0.
35
D
ex
te
rit
y
sc
or
e
0.
99
(0
.0
9)
0.
99
(0
.0
9)
−
0.
00
(−
0.
02
to
0.
01
)
0.
79
−
0.
00
(−
0.
02
to
0.
01
)
0.
76
E
m
ot
io
n
sc
or
e
0.
99
(0
.0
4)
0.
99
(0
.0
3)
−
0.
01
(−
0.
01
to
0.
00
)
0.
10
−
0.
01
(−
0.
01
to
0.
00
)
0.
10
C
og
ni
tio
n
sc
or
e
0.
93
(0
.1
4)
0.
94
(0
.1
3)
−
0.
01
(−
0.
03
to
0.
01
)
0.
51
−
0.
01
(−
0.
03
to
0.
01
)
0.
47
P
ai
n
sc
or
e
0.
99
(0
.0
6)
0.
99
(0
.0
3)
−
0.
01
(−
0.
01
to
0.
00
)
0.
13
−
0.
01
(−
0.
01
to
0.
00
)
0.
13
O
ve
ra
ll
sc
or
e
0.
89
(0
.1
8)
0.
90
(0
.1
7)
−
0.
01
(−
0.
04
to
0.
02
)
0.
46
−
0.
01
(−
0.
04
to
0.
02
)
0.
43
P
ae
di
at
ric
Q
ua
lit
y
of
Li
fe
In
ve
nt
or
y*
*
P
hy
si
ca
lf
un
ct
io
ni
ng
sc
or
e
87
.2
(1
7.
6)
87
.7
(1
7.
1)
−
0.
5
(−
3.
4
to
2.
4)
0.
75
−
0.
5
(−
3.
5
to
2.
4)
0.
72
E
m
ot
io
na
lf
un
ct
io
ni
ng
sc
or
e
75
.1
(1
9.
1)
77
.9
(1
6.
4)
−
2.
8
(−
6.
0
to
0.
4)
0.
09
−
2.
8
(−
6.
0
to
0.
4)
0.
09
S
oc
ia
lf
un
ct
io
ni
ng
sc
or
e
81
.4
(2
0.
2)
83
.7
(1
9.
3)
−
2.
3
(−
5.
6
to
1.
0)
0.
17
−
2.
3
(−
5.
6
to
0.
9)
0.
16
S
ch
oo
lf
un
ct
io
ni
ng
sc
or
e
75
.6
(1
9.
7)
76
.4
(1
9.
7)
−
0.
9
(−
4.
3
to
2.
5)
0.
62
−
0.
8
(−
4.
1
to
2.
4)
0.
61
P
sy
ch
os
oc
ia
lh
ea
lth
su
m
m
ar
y
sc
or
e
77
.4
(1
6.
4)
79
.4
(1
5.
5)
−
2.
0
(−
4.
8
to
0.
8)
0.
17
−
2.
0
(−
4.
7
to
0.
8)
0.
16
P
hy
si
ca
lh
ea
lth
su
m
m
ar
y
sc
or
e
87
.2
(1
7.
6)
87
.7
(1
7.
1)
−
0.
5
(−
3.
4
to
2.
4)
0.
75
−
0.
5
(−
3.
5
to
2.
4)
0.
72 Co
nt
in
ue
d
Collins CT, et al. BMJ Open 2015;5:e007314. doi:10.1136/bmjopen-2014-007314 7
Open Access
group.bmj.com on February 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
In secondary outcomes, there was a signiﬁcant sex by
treatment interaction effect in the Metacognition index
(p=0.03) and Global Executive composite score (p=0.04)
of the BRIEF parent report questionnaire. The
Metacognition index assesses the ability to initiate, plan,
organise, self-monitor and sustain working memory and
the Global Executive composite is a summary score incorp-
orating all the BRIEF clinical scales; scores >64 are indica-
tive of a potential clinical problem. While both groups
achieved scores in the normal range, girls in the high-DHA
group scored signiﬁcantly higher in both the
Metacognition index and Global Executive composite com-
pared with the standard-DHA group (see web appendix B).
There was no signiﬁcant sex by treatment interaction
effect for the total difﬁculties scale of the Strengths
and Difﬁculties Questionnaire, or for any of the other
scales except conduct problems (p=0.003). Both
groups achieved a conduct problems score in the
normal range (scores >3 are indicative of dysfunction),
but girls in the high-DHA group scored signiﬁcantly
higher compared with girls in the standard-DHA group
(see web appendix B). Subgroup analyses by sex for all
primary and secondary outcomes are reported in web
appendix A and B.
Subgroup analysis by randomisation strata—birth weight
<1250 or ≥1250 g
There was no evidence of effect measure modiﬁcation
by birthweight strata for any outcome. Web appendices
C and D show primary and secondary outcomes by birth-
weight strata.
DISCUSSION
Principal findings
Our data indicate that supplementing enteral feeds with
DHA at ≈1% of total fatty acids from within the ﬁrst week
of life to 40 weeks’ CA in children born at less than
33 weeks’ gestation did not beneﬁt IQ, attention, executive
function, behaviour, visual-spatial perceptual skills, educa-
tional progress and quality of life at 7 years’ CA compared
with a standard-DHA diet (≈0.35% total fatty acids).
In prespeciﬁed subgroup analyses, parent-reported
assessments indicated that girls in the high-DHA group
had poorer executive function and more behavioural pro-
blems than girls in the standard-DHA group. The differ-
ences found may be due to chance, particularly given the
high number of statistical comparisons, or may indicate a
true underlying adverse effect of supplementation.
Women in the high-DHA group were more likely to cor-
rectly guess their group allocation,6 so it is also possible
that they had higher expectations of their children com-
pared with women in the standard-DHA group. It is
important to note that these results are inconsistent with
those from direct assessment of executive function (the
Rey Complex Figure and Fruit Stroop Test), which did not
demonstrate differences between groups. There was no
effect of birth weight (<1250 or ≥1250 g) on any outcome.
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Strengths and limitations
This 7-year follow-up of our randomised controlled trial
of preterm born children is the only study to evaluate
the effect a diet that provides the estimated in utero
accretion rate of DHA in infancy has on neurodevelop-
mental outcomes in the early school years. The strengths
of the study include the sample size which was large
enough to detect a four-point difference in Full Scale IQ
if it existed, the low risk of bias achieved through blind-
ing of research personnel, outcome assessors and partici-
pants (apart from the 12 families that requested to be
unblinded), and the minimal rate of attrition. The
follow-up had clinically relevant prespeciﬁed primary
and secondary outcomes and a prespeciﬁed analysis
plan. Robust objective assessments of neurodevelopmen-
tal outcomes were undertaken by psychologists after
extensive training and ongoing auditing. Our study was
a pragmatic trial involving ﬁve Australian perinatal
centres suggesting generalisability of the results to the
wider preterm infant population in developed countries.
However, the study relied on the infant achieving full
enteral feeds to receive the full dose of DHA delivered
either through human milk or infant formula. DHA is
well absorbed by preterm infants15 and this was reﬂected
in the increase in the erythrocyte membrane phospho-
lipid DHA status of infants in the treatment group.16
The erythrocyte DHA status achieved in the high-DHA
group was greater than previous trials that used lower
DHA doses,17 although it did not quite reach our target
level.18 This may be due to the variation of DHA in
breast milk, maternal compliance and delays in achiev-
ing the full DHA dose from intolerance to enteral feeds.
A limitation of the study was not including a teacher
assessment of the child’s behaviour as the diagnostic
accuracy of both the Strengths and Difﬁculties
Questionnaire and the BRIEF is superior when both
parent and teacher reports are used.19 20
Comparison with other studies
Early DHA intervention trials in preterm infants com-
pared infants that received formula supplemented with
DHA with infants receiving formulas devoid of DHA.
Beneﬁts seen in the supplemented infants led to all
preterm infant formula being supplemented with DHA
at a dose comparable to the standard dose in our trial.
There are only two trials of current clinical relevance,
the DINO trial6 and that of Henriksen et al.5 21 In both
these trials, DHA doses reﬂective of the estimated in
utero accretion rate and inclusive of breast milk feeding
were used.5 6 21 We reported previously that providing
enteral feeds containing DHA at ≈1% total fatty acids
improved visual acuity at 4 months’ CA,7 reduced cogni-
tive delay, improved the neurodevelopment of girls and
was strongly suggestive of improved neurodevelopment
in infants born weighing <1250 g at 18 months’ CA com-
pared with a standard-DHA diet.6 The DINO results
were consistent with the only other preterm infant trial
of high-DHA compared with standard-DHA where
improvement in problem solving was demonstrated at
6 months’ CA5 and in sustained attention at 20 months
of age.21 However, their results need to be interpreted
with caution due to the small sample size and large
attrition.21
Of the earlier studies comparing DHA supplemented
formula with formula containing no DHA, only one trial
has assessed children beyond 18 months of age to deter-
mine cognitive effects of DHA supplementation in
infancy.22 In that study, preterm infants were randomised
to receive formula supplemented with DHA (0.5%)
versus no DHA supplementation to 9 months post-
term.23 As with our study, they found no signiﬁcant dif-
ferences between groups in Full Scale IQ or any cogni-
tive outcome measures at 10 years of age.22 In contrast
to our study, girls who received the DHA supplemented
formula showed greater reading and spelling skills than
girls in the control group.22 Their results, however, need
to be interpreted with caution because of the high risk
of bias due to incomplete outcome data with 55% attri-
tion at the 10-year follow-up.
In a follow-up of a subset of this DINO cohort at 3–
5 years’ CA, no differences in parent-reported behaviour
were detected but the results were limited by the sample
size (n=125).24 However, the parental report of poorer
executive function and conduct problems in girls who
received a high-DHA diet is consistent with results found
in the DHA to Optimize Mother Infant Outcome trial.25
In that trial, women were supplemented with DHA
during pregnancy and children were assessed at 4 years
of age. Poorer scores on some but not all indices of
parent-reported executive function and behaviour were
found, although there was no evidence of effect modiﬁ-
cation by sex.25 Executive function has not been assessed
during childhood in preterm infant DHA supplementa-
tion studies. Given the possibility of poorer executive
function and conduct problems we found in girls who
received a high-DHA diet, it will be important to deter-
mine if there is evidence of a difference in later child-
hood or adolescence. It is possible that the potential
differences found may reduce with age.26
Biological and environmental factors interplay to
inﬂuence cognitive development. In the long term, the
effect of the family and environment may have a greater
inﬂuence on cognitive outcomes.27–29 The most fre-
quent indicator used for the family and environmental
effect on cognitive outcomes in preterm infants has
been maternal education level.27 While a composite
measure of socioeconomic status may provide a more
discriminant indicator, maternal education has consist-
ently been shown to be associated with cognitive achieve-
ment.27 There were no differences in maternal
education level attained between the high-DHA and
standard-DHA groups in our 7-year follow-up and the
education level was similar to the Australian average.
Therefore, at least on this somewhat limited indicator of
socioeconomic status, both groups had the same socio-
economic inﬂuences. A weakening of differences in
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cognitive outcome between 18 months and early child-
hood was also seen in the ‘Caffeine for Apnoea of
Prematurity’ trial where a cognitive beneﬁt was found at
18 months, but by 5 years of age there was no differ-
ence.30 Thus, the early beneﬁts of speciﬁc neonatal
interventions appear to wane in middle childhood, but
this does not discount delayed effects.
Conclusions and policy implications
There is limited evidence that DHA supplementation
given in the ﬁrst months of life to preterm infants bene-
ﬁts school-aged outcomes. Our results indicate that pro-
vision of enteral feeds containing a DHA dose of ≈1%
of total fatty acids in the newborn period provides little
evidence of long-term beneﬁt.
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